• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

J&J to Spend More on R&D With Tax Reform Money

biospaceJanuary 25, 2018

Tag: Johnson & Johnson , Tax


Johnson & Johnson is promising to spend more on research in the health-care sector after changes to the U.S. tax system.

But for now, the world’s biggest health-care company isn’t providing many details on how it may use the extra money from lower tax rates.

"We’re going to look at all of our opportunities but it’s going to be a significant increase," Chief Financial Officer Dominic Caruso said Tuesday in an interview on Bloomberg TV.

Previous:Chinese Tycoon Eyes $500M IPO of Luye Life Sciences' Clinic Arm

Next:Why This Heart Drug Could Be a $5B Blockbuster for Novartis

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

J&J to Spend More on R&D With Tax Reform Money | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Pure Natural CAS 480-18-2 Taxifolin Larch Extract Food Grade 95% 98% Dihydroquercetin Taxifolin Powd

Pure Natural CAS 480-18-2 Taxifolin Larch Extract Food Grade 95% 98% Dihydroquercetin Taxifolin Powd
cefotaxime

cefotaxime
10-Deacetyltaxol

10-Deacetyltaxol

Cefotaxime for injection

Cefotaxime for injection
Paclitaxel

Paclitaxel
Astaxanthin

Astaxanthin
Docetaxel

Docetaxel
Astaxanthin Oleoresin

Astaxanthin Oleoresin
Natural Astaxanthin

Natural Astaxanthin
Astaxanthin

Astaxanthin

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service